Visual Communication: Digital Tool to Improve the Understanding of Treatment Options for Patients With Cancer and Increase Satisfaction of the Overall Experience for Patients, Caregivers, and Providers

NCT ID: NCT06927050

Last Updated: 2025-04-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-14

Study Completion Date

2026-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study in patients with newly diagnosed cancer to prospectively evaluate the feasibility of integration of a visual communication tool for patients/caregivers/providers by determining whether such a tool can increase overall satisfaction with the patient experience.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients (and caregivers) recently diagnosed with cancer

Enrolled patients will receive a tool during the patient consultation encounter to explain their disease location and stage, role of radiation, logistics of radiation treatment delivery and sequencing of treatment. Following the encounter, a survey will be provided.

If patients are accompanied by a caregiver(s), they will also receive a survey.

Group Type EXPERIMENTAL

Visual Communication Tool

Intervention Type BEHAVIORAL

MyCareGorithm will be used during the patient consultation encounter to explain their disease location and stage, role of radiation, logistics of radiation treatment delivery and sequencing of treatment. MyCareGorithm is an online educational tool that will be displayed to the patient via iPad or Microsoft tablet.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Visual Communication Tool

MyCareGorithm will be used during the patient consultation encounter to explain their disease location and stage, role of radiation, logistics of radiation treatment delivery and sequencing of treatment. MyCareGorithm is an online educational tool that will be displayed to the patient via iPad or Microsoft tablet.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MyCareGorithm

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients:

* Patients seen in consultation from 12/1/2024-6/1/2025
* Patients aged 18 years to 100 years old
* Patients with a malignancy of breast or head and neck
* English speaking patients
* Patients being treated with definitive intent
* Patients treated at NYU Langone Health for their malignancy
* Willing and able to provide consent

Caregivers:

Exclusion Criteria

* Willing and able to provide consent

Providers:

* Doctors and nurse practitioners in medical oncology and radiation oncology, and in the ear nose throat (ENT) department.
* Willing and able to provide consent
* aged 18 years to 100 years old


Patients:

* Patients with any other site of disease other than listed above
* Non-English-speaking patients, as the tool is currently available in English only. Translation into additional languages such as Spanish and Russian is currently in process.
* Patient unable to complete the survey portion of the study independently

Caregivers:

• Unable to complete the survey portion of the study independently
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

NYU Langone Health

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jason Domogauer, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

NYU Langone Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

NYU Langone Health

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jason Domogauer, MD, PhD

Role: CONTACT

(212) 501-5003

Julie Xiao

Role: CONTACT

(646) 501-2918

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

24-01870

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.